27348517|t|Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel - Chelator Complex on Biodistribution and Tumor Uptake
27348517|a|Bradykinin B1 receptor (B1R), which is upregulated in a variety of malignancies, is an attractive cancer imaging biomarker. In this study we optimized the selection of radiolabel - chelator complex to improve tumor uptake and tumor -to-background contrast of radiolabeled analogues of B9958 (Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg), a potent B1R antagonist. Peptide sequences were assembled on solid phase. Cold standards were prepared by incubating DOTA -/ NODA - conjugated peptides with GaCl3, and by incubating AlOH - NODA -conjugated peptide with NaF. Binding affinities were measured via in vitro competition binding assays. (68)Ga and (18)F labeling experiments were performed in acidic buffer and purified by HPLC. Imaging / biodistribution studies were performed in mice bearing both B1R-positive (B1R+) HEK293T :: hB1R and B1R-negative (B1R-) HEK293T tumors. Z02176 (Ga-DOTA-Pip-B9958; Pip: 4-amino-(1-carboxymethyl)piperidine), Z02137 (Ga-NODA-Mpaa-Pip-B9958; Mpaa: 4-methylphenylacetic acid), and Z04139 (AlF-NODA-Mpaa-Pip-B9958) bound h B1R with high affinity (Ki = 1.4-2.5 nM). (68)Ga -/ (18)F - labeled peptides were obtained on average in ≥32% decay-corrected radiochemical yield with >99% radiochemical purity and 100-261 GBq/μmol specific activity. Biodistribution / imaging studies at 1 h postinjection showed that all tracers cleared rapidly from background tissues (except kidneys) and were excreted predominantly via the renal pathway. Only kidneys, bladders, and B1R+ tumors were clearly visualized in PET images. Uptake in B1R+ tumor was higher by using (68)Ga - Z02176 (28.9 ± 6.21 %ID/g) and (18)F - Z04139 (22.6 ± 3.41 %ID/g) than (68)Ga - Z02137 (14.0 ± 4.86 %ID/g). The B1R+ tumor-to-blood and B1R+ tumor-to-muscle contrast ratios were also higher for (68)Ga - Z02176 (56.1 ± 17.3 and 167 ± 57.6) and (18)F - Z04139 (58.0 ± 20.9 and 173 ± 42.9) than (68)Ga - Z02137 (34.3 ± 15.2 and 103 ± 30.2). With improved target-to-background contrast (68)Ga - Z02176 and (18)F - Z04139 are promising for imaging B1R expression in cancers with PET.
27348517	0	12	Radiolabeled	T080	C1527121
27348517	13	30	B9958 Derivatives	T104	C0002776
27348517	35	42	Imaging	T060	C0011923
27348517	43	65	Bradykinin B1 Receptor	T116,T192	C0384601
27348517	66	76	Expression	T045	C1171362
27348517	82	110	Positron Emission Tomography	T060	C0032743
27348517	126	136	Radiolabel	T130	C0597354
27348517	139	147	Chelator	T121,T130	C0007974
27348517	148	155	Complex	T104	C1704241
27348517	159	174	Biodistribution	T169	C1704711
27348517	179	184	Tumor	T191	C0027651
27348517	185	191	Uptake	T043	C3888108
27348517	192	214	Bradykinin B1 receptor	T116,T192	C0384601
27348517	216	219	B1R	T116,T192	C0384601
27348517	231	242	upregulated	T044	C0041904
27348517	259	271	malignancies	T191	C0006826
27348517	290	304	cancer imaging	T060	C1655037
27348517	305	314	biomarker	T201	C0005516
27348517	324	329	study	T062	C2603343
27348517	360	370	radiolabel	T130	C0597354
27348517	373	381	chelator	T121,T130	C0007974
27348517	382	389	complex	T104	C1704241
27348517	401	406	tumor	T191	C0027651
27348517	407	413	uptake	T043	C3888108
27348517	418	423	tumor	T191	C0027651
27348517	451	463	radiolabeled	T080	C1527121
27348517	464	473	analogues	T116	C0597191
27348517	477	482	B9958	T116	C1721886
27348517	484	525	Lys-Lys-Arg-Pro-Hyp-Gly-Cpg-Ser-d-Tic-Cpg	T087	C0920679
27348517	537	551	B1R antagonist	T121	C3850093
27348517	553	570	Peptide sequences	T116	C0030956
27348517	589	600	solid phase	T052	C3178929
27348517	602	616	Cold standards	T080	C1442989
27348517	645	649	DOTA	T109,T121	C0088359
27348517	653	657	NODA	T109	C0029224
27348517	660	670	conjugated	T082	C0522529
27348517	671	679	peptides	T116	C0030956
27348517	685	690	GaCl3	T197	C0021521
27348517	710	714	AlOH	T121,T197	C0002371
27348517	717	721	NODA	T109	C0029224
27348517	734	741	peptide	T116	C0030956
27348517	747	750	NaF	T122,T197	C0037508
27348517	752	759	Binding	T044	C1167622
27348517	760	770	affinities	T070	C1510827
27348517	789	824	in vitro competition binding assays	T059	C0201712
27348517	826	832	(68)Ga	T130,T196	C0303226
27348517	837	842	(18)F	T130,T196	C0302995
27348517	843	863	labeling experiments	T062	C0022261
27348517	882	895	acidic buffer	T121,T130	C0006353
27348517	912	916	HPLC	T059	C0008562
27348517	918	925	Imaging	T060	C0011923
27348517	928	943	biodistribution	T169	C1704711
27348517	944	951	studies	T062	C2603343
27348517	970	974	mice	T015	C0025929
27348517	988	1000	B1R-positive	T116,T192	C0384601
27348517	1002	1006	B1R+	T116,T192	C0384601
27348517	1008	1015	HEK293T	T025	C0007634
27348517	1019	1023	hB1R	T025	C0007634
27348517	1028	1040	B1R-negative	T033	C1513916
27348517	1042	1046	B1R-	T033	C1513916
27348517	1048	1055	HEK293T	T025	C0007634
27348517	1056	1062	tumors	T191	C0027651
27348517	1064	1070	Z02176	T116	C0030956
27348517	1072	1089	Ga-DOTA-Pip-B9958	T116	C0030956
27348517	1091	1094	Pip	T109	C0031960
27348517	1096	1132	4-amino-(1-carboxymethyl)piperidine)	T109	C0031960
27348517	1134	1140	Z02137	T116	C0030956
27348517	1142	1164	Ga-NODA-Mpaa-Pip-B9958	T116	C0030956
27348517	1166	1170	Mpaa	T109,T121	C0070620
27348517	1172	1197	4-methylphenylacetic acid	T109,T121	C0070620
27348517	1204	1210	Z04139	T116	C0030956
27348517	1212	1235	AlF-NODA-Mpaa-Pip-B9958	T116	C0030956
27348517	1245	1248	B1R	T116,T192	C0384601
27348517	1259	1267	affinity	T070	C1510827
27348517	1287	1293	(68)Ga	T130,T196	C0303226
27348517	1297	1302	(18)F	T130,T196	C0302995
27348517	1305	1312	labeled	T080	C1708632
27348517	1313	1321	peptides	T116	C0030956
27348517	1371	1384	radiochemical	T120	C0599914
27348517	1385	1390	yield	T081	C0392762
27348517	1401	1414	radiochemical	T120	C0599914
27348517	1415	1421	purity	T081	C1882508
27348517	1443	1451	specific	T080	C0205369
27348517	1452	1460	activity	T052	C0441655
27348517	1462	1477	Biodistribution	T169	C1704711
27348517	1480	1487	imaging	T060	C0011923
27348517	1488	1495	studies	T062	C2603343
27348517	1501	1502	h	T079	C0439227
27348517	1533	1540	tracers	T130	C1522485
27348517	1573	1580	tissues	T024	C0040300
27348517	1589	1596	kidneys	T023	C0022646
27348517	1607	1615	excreted	T039	C0221102
27348517	1638	1651	renal pathway	T042	C0035070
27348517	1658	1665	kidneys	T023	C0022646
27348517	1667	1675	bladders	T023	C0005682
27348517	1681	1685	B1R+	T116,T192	C0384601
27348517	1686	1692	tumors	T191	C0027651
27348517	1720	1723	PET	T060	C0032743
27348517	1724	1730	images	T170	C1704922
27348517	1732	1738	Uptake	T043	C3888108
27348517	1742	1746	B1R+	T116,T192	C0384601
27348517	1747	1752	tumor	T191	C0027651
27348517	1773	1779	(68)Ga	T130,T196	C0303226
27348517	1782	1788	Z02176	T116	C0030956
27348517	1813	1818	(18)F	T130,T196	C0303226
27348517	1821	1827	Z04139	T116	C0030956
27348517	1853	1859	(68)Ga	T130,T196	C0303226
27348517	1862	1868	Z02137	T116	C0030956
27348517	1894	1913	B1R+ tumor-to-blood	T081	C0456603
27348517	1918	1954	B1R+ tumor-to-muscle contrast ratios	T081	C0456603
27348517	1976	1982	(68)Ga	T130,T196	C0303226
27348517	1985	1991	Z02176	T116	C0030956
27348517	2025	2030	(18)F	T130,T196	C0303226
27348517	2033	2039	Z04139	T116	C0030956
27348517	2074	2080	(68)Ga	T130,T196	C0303226
27348517	2083	2089	Z02137	T116	C0030956
27348517	2134	2163	target-to-background contrast	T080	C1979874
27348517	2164	2170	(68)Ga	T130,T196	C0303226
27348517	2173	2179	Z02176	T116	C0030956
27348517	2184	2189	(18)F	T130,T196	C0303226
27348517	2192	2198	Z04139	T116	C0030956
27348517	2217	2224	imaging	T060	C0011923
27348517	2225	2228	B1R	T116,T192	C0384601
27348517	2229	2239	expression	T045	C1171362
27348517	2243	2250	cancers	T191	C0006826
27348517	2256	2259	PET	T060	C0032743